Olivier Querolle and Luca Iacovino and Andreas Goutopoulos and Tian Jin and Zaixu Xu and Marta Malattia and Nicolas Bocquet and Alena Freudenmann and Marina Gysin and Hanna Kok and Jason Clochard and Roxanne Lourman and Anika Kuster and Serena Bologna and Irena Konstantinova and Sotirios K. Sotiriou and Thanos D. Halazonetis and James Mills and Ronen Gabizon and Almog Nadir and Nir London and Tarig Bashir and Frank T. Zenke and Ulrich Lücking
ChemRxiv. 10 November 2026.
DOI: https://doi.org/10.26434/chemrxiv.15011922/v1
Poly(ADP-ribose) glycohydrolase (PARG) is the principal enzyme responsible for the degradation of poly(ADP-ribose) chains and has emerged as a promising therapeutic target in oncology within the DNA damage response (DDR) field. Although several reversible PARG inhibitors have recently entered clinical development, covalent inhibition of PARG has not previously been described. Herein, we report the discovery and optimization of the first covalent PARG inhibitors. Guided by structural analysis of the PARG catalytic domain, electrophilic warheads were incorporated into reversible quinazolinedione-based inhibitors to enable selective engagement of Cys872, a residue located within the catalytic pocket. While unsaturated ketone and hydrazide warheads enabled covalent inhibition of PARG, incorporation of a bicyclo[1.1.0]butane (BCB) hydrazide warhead led to the discovery of FORX-175, combining potent biochemical and cellular activity, reduced electrophile reactivity, and improved covalent-labeling selectivity. To the best of our knowledge, this work represents the first application of a BCB hydrazide warhead for selective covalent cysteine targeting. Building on these findings, a hybrid design strategy combining structural elements of the covalent quinazolinedione series with those of a reversible PARG inhibitor series led to the discovery of FORX-425, a covalent quinoline inhibitor bearing an underexplored BCB-carboxamide warhead. FORX-425 displayed potent biochemical inhibition, efficient covalent engagement, and nanomolar cellular activity in PARG-sensitive cancer cell lines. Collectively, these studies establish covalent inhibition as a viable strategy for PARG modulation, identify Cys872 as a tractable site for selective covalent targeting, and further demonstrate the potential of BCB-derived warheads for cysteine-directed drug discovery.